Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Celgene Corporation (CELG - Analyst Report) boasts of an interesting and diversified pipeline. Multiple pipeline-related news are expected in the coming quarters. Celgene is highly optimistic on the potential of apremilast, which is being developed for multiple indications such as moderate-to-severe psoriasis and psoriatic arthritis among others.

Celgene is seeking U.S. approval for apremilast in the psoriatic arthritis indication. Approval has also been sought for the same indication in Canada. Celgene is also evaluating apremilast in patients suffering from moderate-to-severe psoriasis. U.S. approval for the moderate-to-severe psoriasis indication is expected to be sought by Dec 31, 2013. Moreover, Celgene intends to seek EU approval for apremilast in the psoriasis and psoriatic arthritis indications by year end.

Results of pre-specified sub-analyses from the phase III (ESTEEM 1) study revealed significant improvement in apremilast treated patients suffering from nail and scalp psoriasis at 16 weeks. Results further revealed that the patients continued to show improvements through 32 weeks. Moreover, apremilast treatment caused significant improvements in health-related quality-of-life parameters in plaque psoriasis patients. The improvements witnessed at week 16 were maintained through week 32.

Apremilast is also undergoing phase III studies in the ankylosing spondylitis indication. The candidate is also being evaluated for treating patients suffering from Behçet’s disease (encouraging results from a phase II study were presented in Jun 2013). Celgene is also advancing the development of the early-stage candidates in its pipeline. We believe that the successful development and commercialization of the pipeline would boost Celgene’s top line further.

Celgene, a biopharmaceutical company, currently carries a Zacks Rank #3 (Hold). Actelion Ltd. (ALIOF), Athersys, Inc. (ATHX - Snapshot Report) and Alexion Pharmaceuticals, Inc. (ALXN - Analyst Report) appear to be well placed in the biopharma space. Actelion carries a Zacks Rank #1 (Strong Buy) while Alexion and Athersys are Zacks #2 Ranked (Buy) stocks.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GENERAL FINA GFN 8.20 +5.67%
QIHOO 360 TE QIHU 91.57 +4.38%
VIPSHOP HOLD VIPS 140.01 +3.49%
INVESTMENT T ITG 19.16 +3.34%
VERTEX ENERG VTNR 7.38 +3.07%